ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (NASDAQ: SCRX) today announced that the U.S. Food & Drug Administration (FDA) has approved all four dosage strengths of the new Sular® formulation. The new Sular formulation, which utilizes SkyePharma’s (LSE:SKP) patented GEOMATRIX™ technology, provides a lower dose of Sular for each of its current doses. The Company expects to launch the new Sular formulation during the first quarter of 2008.
